Li Ka-shing contributes to £11m boost for cancer breath test
Published on: 5 Mar 2018
The Sunday Times reports that Owlstone Medical® has raised a $15m (£11m) investment for its Breath Biopsy® platform.
You can read the Sunday Times article below:
Li Ka-shing contributes to £11m boost for cancer ‘breath test’ company Owlstone Medical
Hong Kong billionaire Li Ka-shing is among investors to have ploughed $15m (£11m) into a Cambridge company that has developed a “breath test” for cancer.
Li’s investment arm, Horizon Ventures, was joined by Aviva Ventures in backing Owlstone Medical to launch its lung cancer breath biopsy.
Owlstone was founded by engineer Billy Boyle, 39, whose wife died of cancer in 2014. The father-of-two vowed to help prevent other families suffering the loss of a loved one because of a late-stage diagnosis.
His technology can also be used to check for other diseases, such as asthma, and in precision medicine — to ensure the right drug is given at the right time.
Pharma giants including Glaxo Smith Kline are working with Owlstone to identify patients who will respond to their drugs.
Breath Biopsy®
If you want to learn more about how Owlstone Medical’s Breath Sampling and Analysis technology and Services are helping to research novel solutions for early detection and precision medicine, why not download our free ebook: Breath Biopsy: The Complete Guide?
